Recent findings from various trials of SGLT2 inhibitors including the renally dedicated CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial showed that SGLT2 inhibition reduced the risk of cardiovascular and renal events in type 2 diabetes regardless of HbA1c [57], suggesting that the management of complications associated with type 2 diabetes continues to improve. This evidence concerns the gene SLC5A2 and diabetes mellitus.